Effect of systemic injection of heterogenous and homogenous opioids on peripheral cellular immune response in rats with bone cancer pain: A comparative study

Du,Jun‑Ying; Liang,Yi; Fang,Jun‑Fan; Jiang,Yong‑Liang; Shao,Xiao‑Mei; He,Xiao‑Fen; Fang,Jian‑Qiao

doi:10.3892/etm.2016.3647

Effect of systemic injection of heterogenous and homogenous opioids on peripheral cellular immune response in rats with bone cancer pain: A comparative study

Authors:
- Jun‑Ying Du
- Yi Liang
- Jun‑Fan Fang
- Yong‑Liang Jiang
- Xiao‑Mei Shao
- Xiao‑Fen He
- Jian‑Qiao Fang
View Affiliations

Affiliations: Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China
Published online on: September 1, 2016 https://doi.org/10.3892/etm.2016.3647
Pages: 2568-2576
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Exogenous and endogenous opioids have been shown to modulate the immune system. Morphine-induced immunosuppression has been investigated extensively. However, the immune‑regulating function of endogenous opioid peptides is unclear. The present study aimed to evaluate the difference in effects on cellular immune function between recombinant rat β‑endorphin (β-EP; 50 µg/kg) and plant source morphine (10 mg/kg) via intraperitoneal injection treatment in a rat model of bone cancer pain. Walker 256 cells were injected into a tibial cavity injection to establish the bone cancer pain model. The paw withdrawal thresholds and body weights were measured prior to surgery, at 6 days after surgery, and following 1, 3,6 and 8 treatments. The spleen cells were harvested for detection of T cell proliferation, natural killer (NK) cell cytotoxicity, and the relative quantities of T cell subtypes (CD3+, CD4+ and CD8+ cells). Plasma levels of interleukin‑2 (IL‑2) were also determined. It was found that single or multiple treatments with β‑EP (a homogenous opioid peptide) and morphine (a heterogenous opioid) had good analgesic effects on bone cancer pain, while the analgesia provided by morphine was stronger than that of β‑EP. Treatment with β‑EP 3, 6 and 8 times increased the body weight gain in the rat model of bone cancer pain, while morphine treatment had on effect on it. With regard to immunomodulatory functions, β‑EP treatment increased T cell proliferation and NK cell cytotoxicity, and increased the relative quantities of T cell subtypes, but no effect on T cell secretion. However, morphine treatment decreased T cell proliferation and the levels of T cell subtypes. These data indicate that opioids from different sources have different effects on cellular immune function in vivo. A small dose of homogenous opioid peptide exhibited positive effects (analgesia and immune enhancement) on cancer pain. These results provide experimental evidence supporting the exploitation of human opioids for the treatment of cancer pain.

View Figures

View References

1	Mercadante S and Fulfaro F: Management of painful bone metastases. Curr Opin Oncol. 19:308–314. 2007. View Article : Google Scholar : PubMed/NCBI
2	Marcus DA: Epidemiology of cancer pain. Curr Pain Headache Rep. 15:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
3	Pignon T, Fernandez L, Ayasso S, Durand MA, Badinand D and Cowen D: Impact of radiation oncology practice on pain: A cross-sectional survey. Int J Radiat Oncol Biol Phys. 60:1204–1210. 2004. View Article : Google Scholar : PubMed/NCBI
4	Rietman JS, Dijkstra PU, Debreczeni R, Geertzen JH, Robinson DP and De Vries J: Impairments, disabilities and health related quality of life after treatment for breast cancer: A follow-up study 2.7 years after surgery. Disabil Rehabil. 26:78–84. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wilson KG, Graham ID, Viola RA, Chater S, de Faye BJ, Weaver LA and Lachance JA: Structured interview assessment of symptoms and concerns in palliative care. Can J Psychiatry. 49:350–358. 2004.PubMed/NCBI
6	van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M and Patijn J: Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Ann Oncol. 18:1437–1449. 2007. View Article : Google Scholar : PubMed/NCBI
7	Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR and Mantyh PW: Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience. 98:585–598. 2000. View Article : Google Scholar : PubMed/NCBI
8	Schwab JM, Zhang Y, Kopp MA, Brommer B and Popovich PG: The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury. Exp Neurol. 258:121–129. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chen HY, Li SG, Cho WC and Zhang ZJ: The role of acupoint stimulation as an adjunct therapy for lung cancer: A systematic review and meta-analysis. BMC Complement Altern Med. 13:3622013. View Article : Google Scholar : PubMed/NCBI
10	Sacerdote P: Opioid-induced immunosuppression. Curr Opin Support Palliat Care. 2:14–18. 2008. View Article : Google Scholar : PubMed/NCBI
11	Smith RJ, Rhodes K, Paciotti B, Kelly S, Perrone J and Meisel ZF: Patient perspectives of acute pain management in the era of the opioid epidemic. Ann Emerg Med. 66:246–252, e1. 2015. View Article : Google Scholar : PubMed/NCBI
12	Kostev K, Wartenberg F, Richter H, Reinwald M and Heilmaier C: Persistence with opioid treatment in Germany in patients suffering from chronic non-malignant or cancer pain. Curr Med Res Opin. 31:1157–1163. 2015. View Article : Google Scholar : PubMed/NCBI
13	Deyo RA, Von Korff M and Duhrkoop D: Opioids for low back pain. BMJ. 350:g63802015. View Article : Google Scholar : PubMed/NCBI
14	Stefano GB, Fricchione G, Goumon Y and Esch T: Pain, immunity, opiate and opioid compounds and health. Med Sci Monit. 11:MS47–MS53. 2005.PubMed/NCBI
15	Vallejo R, de Leon-Casasola O and Benyamin R: Opioid therapy and immunosuppression: A review. Am J Ther. 11:354–365. 2004. View Article : Google Scholar : PubMed/NCBI
16	Sacerdote P: Opioids and the immune system. Palliat Med. 20 Suppl 1:S9–S15. 2006.PubMed/NCBI
17	Fang JQ, Du JY, Liang Y and Fang JF: Intervention of electroacupuncture on spinal p38 MAPK/ATF-2/VR-1 pathway in treating inflammatory pain induced by CFA in rats. Mol Pain. 9:132013. View Article : Google Scholar : PubMed/NCBI
18	Poli A, Brons NH, Ammerlaan W, Michel T, Hentges F, Chekenya M and Zimmer J: Novel method for isolating untouched rat natural killer cells with higher purity compared with positive selection and fluorescence-activated cell sorting. Immunology. 131:386–394. 2010. View Article : Google Scholar : PubMed/NCBI
19	Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF, Zhang YQ, Wu GC and Wang YQ: A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun. 345:1292–1298. 2006. View Article : Google Scholar : PubMed/NCBI
20	Jun-Ying D, Yi L, Yi-Tian C, et al: Functional evaluation of spleen T lymphocytes in the rat model of Walker-256 bone cancer pain. Zhong Guo Bi Jiao Yi Xue Za Zhi. 24:8-13MS2014.(In Chinese).
21	Wennerberg E, Kremer V, Childs R and Lundqvist A: CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother. 64:225–235. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L, Deng W, Ring AM, Fischer S, Garcia KC and Raulet DH: Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest. 124:4781–4794. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zitvogel L and Kroemer G: Cytokines reinstate NK cell-mediated cancer immunosurveillance. J Clin Invest. 124:4687–4689. 2014. View Article : Google Scholar : PubMed/NCBI
24	Shereck E, Satwani P, Morris E and Cairo MS: Human natural killer cells in health and disease. Pediatr Blood Cancer. 49:615–623. 2007. View Article : Google Scholar : PubMed/NCBI
25	Saijo N, Ozaki A, Beppu Y, Takahashi K, Fujita J, Sasaki Y, Nomori H, Kimata M, Shimizu E and Hoshi A: Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GM1 antibody or anticancer agents. J Cancer Res Clin Oncol. 107:157–163. 1984. View Article : Google Scholar : PubMed/NCBI
26	Sacerdote P: Opioid-induced immunosuppression. Curr Opin Support Palliat Care. 2:14–18. 2008. View Article : Google Scholar : PubMed/NCBI
27	Chang MC, Fan SZ, Hsiao PN, Cheng WF and Sun WZ: Influence of morphine on host immunity. Acta Anaesthesiol Taiwan. 49:105–108. 2011. View Article : Google Scholar : PubMed/NCBI
28	Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, et al: Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Mol Cell Proteomics. 11:605–618. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kheav VD, Busson M, Scieux C, de Latour R Peffault, Maki G, Haas P, Mazeron MC, Carmagnat M, Masson E, Xhaard A, et al: Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica. 99:1860–1867. 2014. View Article : Google Scholar : PubMed/NCBI
30	Jacobs B and Ullrich E: The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions? Curr Med Chem. 19:1771–1779. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zhao JX: Advances of enhancing cytotoxicitiy of NK cells. Chinese Journal of Cancer Prevention & Treatment. 16:1267–1271. 2009.
32	Schweizerhof M, Stösser S, Kurejova M, Njoo C, Gangadharan V, Agarwal N, Schmelz M, Bali KK, Michalski CW, Brugger S, et al: Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med. 15:802–807. 2009. View Article : Google Scholar : PubMed/NCBI
33	Sarkar DK, Murugan S, Zhang C and Boyadjieva N: Regulation of cancer progression by β-endorphin neuron. Cancer Res. 72:836–840. 2012. View Article : Google Scholar : PubMed/NCBI
34	Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ and Schreiber RD: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903–907. 2007. View Article : Google Scholar : PubMed/NCBI
35	Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, et al: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 174:2591–2601. 2005. View Article : Google Scholar : PubMed/NCBI
36	Fujii H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kitoh A, Ono M, Matsumura Y, Kato M, Konishi K, et al: CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer. 134:2393–2402. 2014. View Article : Google Scholar : PubMed/NCBI
37	Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP and Behboudi S: Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS One. 9:e881332014. View Article : Google Scholar : PubMed/NCBI
38	Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD and Allen PM: Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 13:265–276. 2000. View Article : Google Scholar : PubMed/NCBI
39	Arancibia-Carcamo CV, Osawa H, Arnett HA, Háskova Z, George AJ, Ono SJ, Ting JP and Streilein JW: A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites. Eur J Immunol. 34:471–480. 2004. View Article : Google Scholar : PubMed/NCBI
40	Boon T, Coulie PG, Van den Eynde BJ and van der Bruggen P: Human T cell responses against melanoma. Annu Rev Immunol. 24:175–208. 2006. View Article : Google Scholar : PubMed/NCBI
41	Segal BM, Glass DD and Shevach EM: Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol. 168:1–4. 2002. View Article : Google Scholar : PubMed/NCBI
42	Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al: Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 207:637–650. 2010. View Article : Google Scholar : PubMed/NCBI
43	Noyan F, Lieke T, Taubert R, Sievers M, Dywicki J, Hapke M, Falk CS, Manns MP, Jaeckel E and Hardtke-Wolenski M: Naive tumour-specific CD4+ T cells were efficiently primed in acute lymphoblastic leukaemia. Scand J Immunol. 80:161–168. 2014. View Article : Google Scholar : PubMed/NCBI
44	Snook AE, Magee MS, Schulz S and Waldman SA: Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol. 44:1956–1966. 2014. View Article : Google Scholar : PubMed/NCBI